Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI-534
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
MEDI-534 is an investigational **live-attenuated intranasal bivalent viral-vectored vaccine** developed by MedImmune for prevention of respiratory syncytial virus and human parainfluenza virus type 3 disease in infants and young children. It is a recombinant chimeric bovine/human parainfluenza virus type 3 construct: a bovine PIV3 backbone incorporates human PIV3 fusion and hemagglutinin-neuraminidase glycoproteins and expresses the respiratory syncytial virus fusion glycoprotein. Intranasal replication of the attenuated vector is intended to induce mucosal and systemic immunity against both RSV and PIV3. Clinical development reached a completed Phase 1/2a study in infants and young children; published analyses reported limited RSV F immunogenicity and transgene-sequence heterogeneity or stability concerns. ([astrazenecaclinicaltrials.com](https://www.astrazenecaclinicaltrials.com/study/MI-CP178/))
- Other names
- respiratory syncytial virus vaccine + parainfluenza virus type 3 vaccineRSV/PIV3 vaccineparainfluenza virus type 3/respiratory syncytial virus vaccine
02
Targets
Respiratory syncytial virus and parainfluenza virus type 3 antigen-specific components of the human immune systemHPIV-3 F (Human parainfluenza virus 3 fusion protein)HN (Hemagglutinin-neuraminidase protein)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on MEDI-534.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI-534.